We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Aureus Licenses AurSCOPE® GPCR to Euroscreen

Aureus Licenses AurSCOPE® GPCR to Euroscreen

Aureus Licenses AurSCOPE® GPCR to Euroscreen

Aureus Licenses AurSCOPE® GPCR to Euroscreen

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureus Licenses AurSCOPE® GPCR to Euroscreen"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aureus Pharma has announced that Euroscreen, SA has become a customer of its AurSCOPE GPCR knowledge database.

Euroscreen joins a growing list of companies using Aureus Pharma's technology, including sanofi-aventis, Roche, and Servier.

AurSCOPE GPCR is designed to provide researchers rapid access to quantitative biological activity data mined from the scientific journals and patents for all known GPCR's, a major class of membrane proteins.   

Euroscreen will use Aureus Pharma's technology in conjunction with their in-house technology to identify GPCR drug candidates. 

“By integrating the Aureus GPCR knowledge database with Euroscreen's research platform, our scientists will be able to rapidly prioritize candidates in lead generation and optimization programs,” said Dr. Francois Roman, Vice President R & D for Euroscreen.

“The information contained within the database will also help us in the design of our chemical libraries for our screening campaigns,” said Dr. Frederic Ooms, Head of Chemistry for Euroscreen.

“As Euroscreen is a world leader in GPCR research, we are pleased they have adopted our AurSCOPE GPCR knowledge base,” said Dr. Andre Michel, CEO of Aureus Pharma.

“AurSCOPE GPCR with its high quality biological and chemical information will complement Euroscreen's technology resulting in an overall acceleration of the discovery process.”